[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562952":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":42,"locations":51,"responsibleParty":71,"collaborators":75,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":27,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":27,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":54,"whyStopped":27,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"TACE plus Lenvatinib","ACTIVE_COMPARATOR","TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.\n\nLenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \\\u003C60 kg) orally once a day )",[13,14],"Procedure: TACE","Drug: Lenvatinb",{"label":16,"type":17,"description":18,"interventionNames":19},"TACE plus Lenvatinib and ablation","EXPERIMENTAL","TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.\n\nLenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \\\u003C60 kg) orally once a day ) Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.",[13,20,14],"Procedure: Ablation",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"PROCEDURE","TACE","TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.",[9,16],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Ablation","Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.",[16],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"DRUG","Lenvatinb","Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \\\u003C60 kg) orally once a day )",[9,16],[38],{"name":39,"affiliation":40,"role":41},"Feng Duan","Chinese PLA General Hospital","STUDY_DIRECTOR",[43,48],{"name":44,"role":45,"phone":46,"phoneExt":27,"email":47},"Qunfang Zhou","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":39,"role":45,"phone":49,"phoneExt":27,"email":50},"86 13910984586","duanfeng@vip.sina.com",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Chinese PLA General hospital","RECRUITING","Beijing","None Selected","100853","China","CN",{"type":61,"coordinates":62},"Point",[63,64],116.39723,39.9075,{"lat":64,"lon":63},[67,69],{"name":44,"role":45,"phone":68,"phoneExt":27,"email":47},"8619868000115",{"name":39,"role":45,"phone":70,"phoneExt":27,"email":50},"8613910984586",{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Zhou Qunfang","Clinical Professor",[76],{"name":40,"class":6},"100562952","the-comparison-of-tace-lenvatinib-with-tace-lenvatinib-ablation-for-intermediate-recurrent-hepatocellular-carcinoma-100562952",false,"NCT06609850","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma: a Multicenter Randomized Control Study","Inclusion Criteria:\n\n1. 18-75 years;\n2. RHCC diagnosed by imaging;\n3. intermediate-stage RHCC (two to three lesions which at least one was \\>3 cm in size or more than three tumors);\n4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;\n5. absence of extrahepatic metastasis or macrovascular invasion;\n6. Child-Pugh class A or B;\n7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.\n8. life expectance \\>3 months;\n\nExclusion Criteria:\n\n1. under 18 years or over 75 years of age;\n2. primary intermediate-stage HCC;\n3. RHCC with more than six tumors, or single RHCC\n\n(5) RHCC \\>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;","ALL","18 Years","75 Years",{"count":88,"type":89},116,"ESTIMATED","INTERVENTIONAL",[92],"NA","Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.",[95,96,97,29,98],"Recurrent Hepatocellular Carcinoma","Lenvatinib","Local Therapy","Systemic Therapy",[34,100,101,102,103],"Hepatocellular carcinoma","Microwave ablation","Radiofrequency ablation","Cryoablation","2024-12-01",{"date":106,"type":107},"2024-12-03","ACTUAL",{"date":109,"type":107},"2024-10-01",{"date":111,"type":89},"2028-10-30",{"name":5,"class":6},1]